Professional Summary
Professional Overview
Margaret Garin is a seasoned pharmaceutical executive with over 15 years of experience in clinical development and research. As the Vice President of Clinical Development at Trevi Therapeutics, Inc., she leads the strategic planning, execution, and oversight of all clinical trials and studies for the company's pipeline of novel therapeutics.
Experience Summary
Current Role
As the VP of Clinical Development at Trevi Therapeutics, Margaret is responsible for driving the company's clinical development strategy and ensuring the successful progression of its investigational drug candidates through all phases of clinical trials. She oversees a team of clinical research professionals and collaborates closely with cross-functional stakeholders to optimize study design, enhance patient recruitment and retention, and maintain regulatory compliance.
Under Margaret's leadership, Trevi Therapeutics has advanced multiple programs into late-stage clinical development, including a Phase 3 study for a promising treatment in the field of rare neurological disorders. She has played a pivotal role in securing funding and forging strategic partnerships to support the company's R&D efforts.
Career Progression
Prior to joining Trevi Therapeutics, Margaret served as the Executive Director of Clinical Development at Bellus Health, where she led the clinical evaluation of the company's lead candidate for chronic cough. She previously held positions of increasing responsibility at Teva Pharmaceuticals, including Senior Director and Director of Clinical Research, where she spearheaded the successful completion of several global clinical trials across various therapeutic areas.
Throughout her career, Margaret has demonstrated a strong track record of advancing drug candidates through the clinical development process, engaging with regulatory agencies, and delivering tangible results that have had a meaningful impact on patient care. Her expertise spans all phases of clinical trials, with a particular focus on rare and specialty disease indications.
Academic Background
Margaret holds a Doctor of Medicine (M.D.) degree from the Medical University of South Carolina and completed her residency in Internal Medicine and fellowship in Endocrinology, Diabetes, and Metabolism at the University of Pennsylvania Health System. She also maintains an academic affiliation as an Adjunct Assistant Professor at Penn Medicine, where she continues to contribute to clinical research and educational initiatives.
Areas of Expertise
- Clinical trial design, planning, and execution
- Regulatory strategy and engagement
- Patient recruitment and retention
- Data management and analysis
- Cross-functional team leadership and collaboration
- Rare and specialty disease drug development
- Endocrinology, diabetes, and metabolism
Professional Impact
Under Margaret's leadership, Trevi Therapeutics has successfully enrolled and completed several key clinical trials, including a Phase 2 study that demonstrated statistically significant improvements in the primary endpoint for patients with a rare neurological disorder. Her strategic guidance and operational expertise have been instrumental in advancing the company's pipeline and positioning it for long-term success.
Conclusion
With her extensive experience in clinical development, strong scientific acumen, and proven track record of delivering results, Margaret Garin is well-positioned to continue driving innovation and advancing Trevi Therapeutics' mission to develop novel therapies that address the unmet needs of patients with rare and debilitating conditions.
